Clinical Trials Browser

Completed × Lymphoma, Large B-Cell, Diffuse × tisagenlecleucel × Clear all

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT04890236 2025-01-20

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Phase EARLY_PHASE1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03610724 2024-06-20

BIANCA

Phase 2 Completed

34 enrolled 19 charts

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02445248 2024-04-18

JULIET

Phase 2 Completed

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05541328 2022-09-15

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

Lymphoma, Large B-Cell, Diffuse

NCT03630159 2022-08-15

PORTIA

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT05349201 2022-07-01

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma